Sahlmann, Carsten-Oliver

[["dc.bibliographiccitation.journal","Annals of Oncology"],["dc.bibliographiccitation.volume","19"],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Lakhani, Vijai J."],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Jung, Werner"],["dc.contributor.author","Glass, Bertram"],["dc.contributor.author","Meller, J."],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Griesinger, Frank"],["dc.date.accessioned","2018-11-07T11:14:10Z"],["dc.date.available","2018-11-07T11:14:10Z"],["dc.date.issued","2008"],["dc.format.extent","184"],["dc.identifier.isi","000256693500359"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/54064"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Oxford Univ Press"],["dc.publisher.place","Oxford"],["dc.relation.conference","10th International Conference on Malignant Lymphoma"],["dc.relation.eventlocation","Lugano, SWITZERLAND"],["dc.relation.issn","0923-7534"],["dc.title","Tandem HD-chemotherapy and myeloablative radioimmunotherapy with 131I-anti-CD20 rituximab in relapsed and refractory B-cell lymphoma: Final results of a phase II study of the German Rait Study Group"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","158"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Case Reports in Oncology"],["dc.bibliographiccitation.lastpage","163"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Schmitz, Katja"],["dc.contributor.author","Engelke, Christoph"],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Hugo, Sara"],["dc.contributor.author","Kellner, Laura"],["dc.contributor.author","Trümper, Lorenz"],["dc.contributor.author","Schildhaus, Hans-Ulrich"],["dc.date.accessioned","2020-12-10T18:37:47Z"],["dc.date.available","2020-12-10T18:37:47Z"],["dc.date.issued","2016"],["dc.identifier.doi","10.1159/000444745"],["dc.identifier.eissn","1662-6575"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77092"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Partial Response to First-Line Crizotinib in an Elderly Male Patient with ROS1 Translocation-Positive Lung Cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","269"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Seminars in Dialysis"],["dc.bibliographiccitation.lastpage","276"],["dc.bibliographiccitation.volume","15"],["dc.contributor.author","Meller, J."],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Becker, W."],["dc.date.accessioned","2018-11-07T10:24:06Z"],["dc.date.available","2018-11-07T10:24:06Z"],["dc.date.issued","2002"],["dc.description.abstract","Nuclear medicine (scintigraphy) studies that are performed in patients being prepared for regular dialysis treatment include the measurement of renal clearance and dynamic studies of renal perfusion and function. Static scintigraphy with 99mTc-DMSA may be used in the evaluation of children at risk of renal damage and further functional deterioration. In patients on peritoneal dialysis, nuclear medicine procedures enable the diagnosis of structural complications such as intra-abdominal herniations and leaks. Diagnosis of infections of the vascular access sites in patients on hemodialysis and of the catheter tunnel in patients on peritoneal dialysis can be made with high diagnostic accuracy using radiolabeled, autologous leukocytes. Scintigraphy is valuable in delineating the extent of deposits of amyloid and parenchymal microcalcifications, and may be helpful in the functional evaluation of organs and tissues involved in the pathophysiology of renal impairment and dialysis. If radioiodine therapy with I-131 is performed in patients on hemodialysis with benign or malignant thyroid disease, then pretherapeutic dosimetry is necessary to avoid over- and undertreatment. Radioiodine therapy in the dialysis patient leads to only insignificant contamination of dialysis equipment and marginal exposure to the medical staff."],["dc.identifier.doi","10.1046/j.1525-139x.2002.00069.x"],["dc.identifier.isi","000177597800008"],["dc.identifier.pmid","12191027"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42595"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Blackwell Publishing Inc"],["dc.relation.issn","0894-0959"],["dc.title","Nuclear medicine studies in the dialysis patient"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","223"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Nuklearmedizin"],["dc.bibliographiccitation.lastpage","227"],["dc.bibliographiccitation.volume","51"],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Meller, J."],["dc.contributor.author","Siggelkow, Heide"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Oezerden, M. M."],["dc.contributor.author","Braune, I."],["dc.contributor.author","Kluge, G."],["dc.contributor.author","Meller, Birgit"],["dc.date.accessioned","2018-11-07T09:14:40Z"],["dc.date.available","2018-11-07T09:14:40Z"],["dc.date.issued","2012"],["dc.description.abstract","The prevalence of cervical lymphadenopathy in autoimmune thyroiditis (AIT) patients is actually unknown. The aim of the study was the detailed retrospective evaluation of 6 index-patients with lymphadenopathy in Robbins level VI and a prospective study with high resolution ultrasound of lymphadenopathy in All patients compared with controls in all compartments of the neck, accessible to sonographic evaluation. Patients, methods: The retrospective study comprises six patients with AIT, evaluated for enlarged Robbins level VI-LN. We report the findings of fine-needle aspiration Cytology, clonal analysis, histology, and serological testing. The prospective study evaluated the prevalence of lymphadenopathy in 49 consecutive patients with AIT (group 1) and 49 consecutive patients with normal thyroids or nontoxic goiter (group2). Results: In the retrospective study, cytology of paratracheal LN revealed reactive lymphoid hyperplasia in 5/6 of the cases and a centroblastic lymphoma in one patient. The presence of monoclonal lymphatic cells was excluded in 5/6 patients and proven in 1/6 patients. Actual viral-infections were ruled out. In the prospective study All-patients showed significantly more enlarged LN in Robbins level II-IV and VI compared to controls. We found no correlation between lymphadenopathy, age, thyroid volume and nodularity, or autoantibody levels. During follow-up in 34 group 1-patients, lymphadenopathy remained stable in 28 patients, and decreased in 6 patients. Conclusion: Lymphadenopathy in Robbins level II-IV and VI is common in AIT-patients and most probably related to the autoimmune process."],["dc.identifier.doi","10.3413/Nukmed-0484-12-03"],["dc.identifier.isi","000312613800004"],["dc.identifier.pmid","23042429"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/27472"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Schattauer Gmbh-verlag Medizin Naturwissenschaften"],["dc.relation.issn","0029-5566"],["dc.title","Patients with autoimmune thyroiditis Prevalence of benign lymphadenopathy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Journal of Nuclear Medicine"],["dc.bibliographiccitation.volume","42"],["dc.contributor.author","Meller, J."],["dc.contributor.author","Altenvoerde, G."],["dc.contributor.author","Lehmann, K."],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Behe, E."],["dc.contributor.author","Becker, W."],["dc.date.accessioned","2018-11-07T09:07:39Z"],["dc.date.available","2018-11-07T09:07:39Z"],["dc.date.issued","2001"],["dc.format.extent","332P"],["dc.identifier.isi","000168821901274"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/25849"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Soc Nuclear Medicine Inc"],["dc.publisher.place","Reston"],["dc.relation.issn","0161-5505"],["dc.title","Fever of unknown origin - Prospective comparison of FDG-imaging with a double head coincidence camera (DHCC) and Ga-67-citrate SPECT."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","424"],["dc.bibliographiccitation.journal","BMC Cancer"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Schaefer, Inga-Marie"],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Schweyer, Stefan"],["dc.contributor.author","Menke, Jan"],["dc.date.accessioned","2018-11-07T09:05:44Z"],["dc.date.available","2018-11-07T09:05:44Z"],["dc.date.issued","2012"],["dc.description.abstract","Background: Pulmonary carcinosarcoma is a biphasic tumour with an unfavourable prognosis. The differential diagnosis includes pulmonary blastoma and is often challenging. Case presentation: We here describe a case of blastomatoid pulmonary carcinosarcoma in a 58-year-old patient, who underwent surgical resection. Histopathological examination revealed immature glandular epithelium resembling high-grade fetal adenocarcinoma expressing epithelial markers and membranous beta-catenin, and blastomatoid spindle cells with partial rhabdomyosarcoma-like differentiation. Both elements expressed p53, MDM2, and cyclin-dependent kinase 4 (CDK4), but not thyroid-transcription factor 1 (TTF-1). Mutation analysis of KRAS, EGFR, and beta-catenin revealed no mutations. Comparative genomic hybridization detected +1q, +6p, +6q24qter, +8q, +11q12q14, +11q23qter, +12q12q21, +12q24qter, +17q, +20q, -5q14q23, -9p13pter, -13q21q21, and amplifications at 12q14q21, 15q24qter, 20q11q12. Conclusion: The observed molecular and cytogenetic findings may provide additional tools for the differential diagnosis of biphasic pulmonary neoplasms. Furthermore, TP53, MDM2, CDK4, and PTPN1 may be involved in tumourigenesis."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2012"],["dc.identifier.doi","10.1186/1471-2407-12-424"],["dc.identifier.isi","000312100800001"],["dc.identifier.pmid","23006472"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/8423"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/25394"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1471-2407"],["dc.rights","CC BY 2.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/2.0"],["dc.title","Blastomatoid pulmonary carcinosarcoma: report of a case with a review of the literature"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","15"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.volume","26"],["dc.contributor.author","Liersch, Thorsten"],["dc.contributor.author","Meller, J."],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Becker, H."],["dc.contributor.author","Goldenberg, David M."],["dc.date.accessioned","2018-11-07T11:15:03Z"],["dc.date.available","2018-11-07T11:15:03Z"],["dc.date.issued","2008"],["dc.identifier.isi","000208457401598"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/54282"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.publisher.place","Alexandria"],["dc.relation.issn","0732-183X"],["dc.title","Repeated anti-CEA-radioimmunotherapy (RAIT) with 131iodine-labetuzumab (phase II study) versus single dose RAIT after salvage resection of colorectal liver metastases (CRC-LM)"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","VI"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Nuklearmedizin"],["dc.bibliographiccitation.lastpage","XI"],["dc.bibliographiccitation.volume","55"],["dc.contributor.author","Fricke, E."],["dc.contributor.author","Koenig, Fatima Barbara"],["dc.contributor.author","Mehl, S."],["dc.contributor.author","Goebell, Peter J."],["dc.contributor.author","Heinzel, A."],["dc.contributor.author","Johannsen, Manfred"],["dc.contributor.author","Mommsen, C."],["dc.contributor.author","Pfister, Daniela"],["dc.contributor.author","Schmidt, D."],["dc.contributor.author","Strauss, A."],["dc.contributor.author","Sahlmann, C.-O."],["dc.date.accessioned","2018-11-07T10:20:02Z"],["dc.date.available","2018-11-07T10:20:02Z"],["dc.date.issued","2016"],["dc.identifier.isi","000384036700010"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41797"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Schattauer Gmbh-verlag Medizin Naturwissenschaften"],["dc.relation.issn","0029-5566"],["dc.title","Interdisciplinary Experience Exchange Radium-223 in clinical Application in osseus metastatic Prostate Cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1182"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Molecular Imaging & Biology"],["dc.bibliographiccitation.lastpage","1191"],["dc.bibliographiccitation.volume","21"],["dc.contributor.author","Kewitz-Hempel, Stefanie"],["dc.contributor.author","Kurch, Lars"],["dc.contributor.author","Cepelova, Michaela"],["dc.contributor.author","Volkmer, Ines"],["dc.contributor.author","Sauerbrey, Axel"],["dc.contributor.author","Conrad, Elke"],["dc.contributor.author","Knirsch, Stephanie"],["dc.contributor.author","Pöpperl, Gabriele"],["dc.contributor.author","Steinbach, Daniel"],["dc.contributor.author","Beer, Ambros J."],["dc.contributor.author","Kramm, Christof M."],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Erdlenbruch, Bernhard"],["dc.contributor.author","Reinbold, Wolf-Dieter"],["dc.contributor.author","Odparlik, Andreas"],["dc.contributor.author","Sabri, Osama"],["dc.contributor.author","Kluge, Regine"],["dc.contributor.author","Staege, Martin S."],["dc.date.accessioned","2020-12-10T14:11:58Z"],["dc.date.available","2020-12-10T14:11:58Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1007/s11307-019-01350-5"],["dc.identifier.eissn","1860-2002"],["dc.identifier.issn","1536-1632"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/71264"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Impact of rs12917 MGMT Polymorphism on [18F]FDG-PET Response in Pediatric Hodgkin Lymphoma (PHL)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1307"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Annals of Hematology"],["dc.bibliographiccitation.lastpage","1315"],["dc.bibliographiccitation.volume","90"],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Sahlmann, Carsten Oliver"],["dc.contributor.author","Lakhani, Vijai J."],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Glass, Bertram"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Meller, Johannes"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Griesinger, Frank"],["dc.date.accessioned","2018-11-07T08:50:15Z"],["dc.date.available","2018-11-07T08:50:15Z"],["dc.date.issued","2011"],["dc.description.abstract","A phase II trial evaluated safety, feasibility and efficacy of a sequential tandem approach combining myeloablative BEAM chemotherapy and autologous stem cell transplantation (ASCT) with myeloablative radioimmunotherapy (HD-RIT), with I-131-anti-CD20 antibody (I-131-rituximab), followed by a second ASCT in patients with relapsed or refractory CD20+ B-cell lymphoma. According to protocol, 16 patients with relapsed (n=14) and refractory (n=2) CD20+ B-cell lymphoma received salvage therapy with rituximab and Dexa-BEAM, followed by BEAM (HD chemotherapy) and high-dose myeloablative radioimmunotherapy 2-6 months after BEAM. Nine of 16 patients received HD-RIT; seven patients were excluded before HD-RIT because of toxicity or progressive disease. Disease histologies were follicular lymphoma (FL) grades 1 and 2 (n=4), transformed follicular (FL 3b; n=6), diffuse large B-cell (DLBCL; n=4), mantle cell (n=1) and marginal zone lymphoma (n=1). After a median follow-up of 50.4 months for OS and 39.7 months for progression-free survival (PFS), estimated 4-year OS and PFS were 67% and 64%, respectively. The estimated 4-year OS and PFS for patients with FL were 80% and 78%, respectively. Toxicity was significant, including one fatal outcome due to pneumonitis. Tandem transplants consisting of HD chemotherapy followed by HD-RIT with I-131-coupled anti-CD20 are manageable and effective but toxic treatment modalities for relapsed poor prognosis CD20+ B-NHL."],["dc.identifier.doi","10.1007/s00277-011-1199-y"],["dc.identifier.isi","000296730300008"],["dc.identifier.pmid","21360108"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/7836"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/21653"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0939-5555"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with I-131-anti-CD20 antibody and stem cell rescue"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]